The effectiveness of intensive post-remission chemotherapy regimens for adult patients with acute lymphoblastic leukemia (ALL) is limited by both a high rate of disease recurrence and a substantial incidence of treatment toxicity. To evaluate a potentially more effective and less toxic approach, we conducted a multicenter phase III trial of consolidation therapies comparing the standard L10M regimen with one combining the brief, intensive L17M regimen and escalating methotrexate (MTX) and L-asparaginase (L-asp). Patients over age 15 with previously untreated ALL were eligible. Induction therapy included vincristine, prednisone, doxorubicin, cyclophosphamide and intrathecal methotrexate administered over 36 days. Patients who achieved complete remission (CR) were randomized to receive consolidation with either the L10M regimen or with DAT (daunomycin, cytosine arabinoside, 6-thioguanine) and escalating MTX and L-asp. The randomization was stratified by age, WBC and Ph chromosome status. Maintenance therapy was the same in both arms. Of 353 eligible patients, 218 (62%) achieved CR and 195 were randomized. The treatment arms did not differ significantly with respect to diseasefree survival (DFS; P = 0.46) or overall survival (P = 0.39). Estimated DFS at 5 years was 32% (95% confidence interval (CI) 23-42%) in the L10M arm and 25% (95% CI 16-33%) in the DAT/MTX/L-asp arm. In each arm, 4% of patients died of toxicities (infection in all but one case). Infections and nausea/vomiting were somewhat more common in the L10M arm (occurring in 68% and 53% of patients respectively) than the DAT/MTX/L-asp arm (56% and 33%). The DAT/MTX/L-asp consolidation regimen was associated with some reduction in nonfatal toxicities, but no significant improvement in DFS, overall survival or non-relapse mortality when compared to the standard L10M regimen. Leukemia (2001) 15, 208-216. 
Introduction
The treatment of adult acute lymphoblastic leukemia (ALL) has not met with the same success achieved in the therapy of childhood ALL, where a complete remission rate of 90% is routinely reported and 5 year survival of 70% is expected. [1] [2] [3] [4] In the early 1980s, several groups reported results suggesting that intensive induction and consolidation therapy could improve the outcome in adults with ALL. For example, the group from Memorial Sloan Kettering using the L10 and L10M regimens reported complete remission rates of 85 and 84%, respectively, with the median survival not being reached at the time these data were published. 5 Most other groups at that time were reporting long-term disease-free survival (DFS) in less than 25% of adults with ALL. 6, 7 The Southwest Oncology Group (SWOG) initiated a study in 1980 to determine the effectiveness of the L10M regimen in a co-operative group setting. That study, SWOG 8001, accrued 182 adult patients between 1980 and 1985. The complete response rate was 68% and the overall survival at 5 years was approximately 30%. 8 However, the consolidation therapy for this protocol was associated with significant toxicity. Five patients died while in remission due to marrow toxicity and there were significant dose reductions after patients received the first cycle of cytosine arabinoside and methotrexate. Repetitive hospitalization for fever and neutropenia was common and the consolidation phase required nearly twice as long to deliver in the SWOG experience than outlined in the initial protocol. In addition, 11 relapses occurred within the first 3 months after complete responses were obtained while the patients were receiving consolidation therapy.
In SWOG 8001, as well as in the Memorial experience, the consolidation phase was the most difficult part of the treatment protocol. Recognizing this problem, Arlin designed the L17M protocol where patients received consolidation therapy utilizing an intensive protocol of daunomycin, cytosine arabinoside, and 6-thioguanine (DAT) and one cycle of cytosine arabinoside. Results from the L17M protocol suggested that this approach provided a less toxic combination while remission duration was not significantly compromised. 9 A potentially effective and relatively nontoxic method of administering methotrexate and L-asparaginase was proposed by Capizzi. 10 In this report, patients with refractory ALL received methotrexate followed by L-asparaginase 24 h later. The sequential administration of these agents appeared to permit significant dose escalation of methotrexate. Several studies employed this approach and suggested a positive correlation between the methotrexate dose delivered and remission duration. 11, 12 Accordingly, the Southwest Oncology Group conducted a study, SWOG 8417/8419, to evaluate a consolidation regimen combining the brief, intensive DAT regimen from the L17M regimen with the Capizzi program of escalating methotrexate and L-asparaginase. The objective of this phase III study was to compare this consolidation regimen to the standard L10M consolidation in terms of disease-free survival, overall survival, and toxicity.
Materials and methods
Adults (age Ͼ15) with newly diagnosed, previously untreated ALL were eligible for entry on to this study, SWOG 8417. Diagnosis of ALL was established by documenting Ͼ50% lymphoblasts in the marrow; when the absolute infiltrate was 30-49%, evidence of progressive disease was necessary. Confir-mation of the diagnosis of ALL by central morphology review was required. Submission of blood or marrow samples for cytogeneic analysis and to a central immunophenotyping laboratory were also required. Additional eligibility requirements included normal renal and hepatic function.
The study was approved by the Institutional Review Board of each participating center. Informed consent was obtained from each patient or parent/legal guardian if the patient was a minor.
Study design
All patients received induction therapy with vincristine, prednisone, doxorubicin, cyclophosphamide, and intrathecal methotrexate (Table 1) . Patients with documented CNS leukemia also received 1800 cGy cranial radiation and 1200 cGy spinal radiation in 200 cGy fractions once a remission bone marrow was obtained.
All patients had a bone marrow examination after completing induction therapy. Those patients with CNS leukemia prior to treatment also had repeat lumbar puncture to document clearance of CNS disease. Patients with a bone marrow demonstrating normal cellularity and fewer than 5% lymphoblasts, peripheral blood recovery with a neutrophil count Ͼ1500/l and a platelet count greater than 100 000/l, and no evidence of extramedullary leukemia were eligible for randomization into one of two consolidation regimens (SWOG 8419).
Consolidation chemotherapy
Patients in either arm began consolidation therapy on day 50. Patients who were randomized to the L10M consolidation (arm I) received methotrexate, cytosine arabinoside (Ara-C), 6-thioguanine, vincristine, prednisone, L-asparaginase, and cyclophosphamide (Table 2) . Patients who were randomized to arm II received daunomycin, cytosine arabinoside, 6-thioguanine, methotrexate and L-asparaginase (Table 2) .
All patients remaining in remission at the completion of consolidation received the same maintenance program that included vincristine, prednisone, doxorubicin, 6-mercaptopurine, methotrexate (intrathecal and orally), dactinomycin, carmustine, and cyclophosphamide (Table 3) . Maintenance therapy was repeated every 21 weeks for 36 months or until relapse. Patients were removed from protocol treatment if relapse was detected at any point during treatment.
Statistical considerations
This study was conducted in two steps, an induction step, designated SWOG-8417, and a post-remission step, SWOG-8419. Patients were initially registered on SWOG-8417 for induction therapy, and those who achieved CR and met the eligibility criteria for SWOG-8419 could then be registered for randomization between post-remission arms I and II. The primary objective of this study was to compare the two postremission arms with respect to survival, disease-free survival (DFS) and toxicity. The study plan called for randomization in SWOG-8419 of 175 patients over a period of 5 years, with 2 additional years' follow-up. This would provide statistical power of 83% to detect a hazard ratio of 1.67 for DFS, based on a two-sided comparison of exponential distributions at the 0.05 critical level, and assuming a median DFS of 80 weeks Leukemia Table 1 Remission induction therapy (SWOG 8417) 13 Further analyses of the effects of treatment and other characteristics were based on logistic regression models for rates of CR and toxicities, and on proportional hazards regression models for survival and DFS. 14, 15 Results of statistical tests are represented by two-tailed P values. The analyses described in this report are based on data available on 17 May 1999.
Results

Remission induction (SWOG-8417) Patients and treatment:
Between July 1985 and May 1991, a total of 404 patients entered the study. Fifty-one were ineligible due to lack of required data, specimens, or material for pathology review (35) , failure to meet diagnostic criteria for ALL (11) , prior treatment (one), receipt of study treatment prior to registration (two), and/or failure to obtain informed consent or IRB approval (two). Characteristics of the 353 eligible patients are summarized in Table 4 .
Of the 353 eligible patients on SWOG-8417, 278 (79%) completed induction therapy as planned. Fifty died while on induction therapy, and nine others were removed from induction early due to various toxicities. Thus, 337 (95%) received all possible induction therapy according to protocol.
Induction results:
Complete response (CR) was obtained in 218 (62%) of the 353 eligible patients. As shown in Table 5 , the CR rate decreased sharply with age, from 71% for patients age 15-34 to 41% for patients age 50 or older. Four of 14 patients (29%, CI 8-58%) with CNS leukemia achieved a CR, compared to 166/264 (63%, CI 57-69%) CNS-negative patients and 48/75 (64%, CI 53-75%) patients with unknown CNS disease status. This difference is particularly striking since the oldest CNS-positive patient was age 50, while 24% of the CNS-negative patients were age 50 or older. Multivariate logistic regression analysis showed that the CR rate was significantly related to independent effects of both age (P Ͻ 0.0001) and CNS involvement (P = 0.013 for positive vs negative vs unknown). There was little difference in CR rate between CNS-negative patients and those with unknown CNS disease status (P = 0.69), which is consistent with the likelihood that most patients with unknown CNS disease status were in fact negative. None of the other factors in Table 4 were significantly related to the CR rate. In particular, neither the peripheral WBC, FAB category nor immunophenotype (T vs B vs null) significantly influenced the CR rate. Additionally, other variables not listed in Table 4 including sex, performance status, liver, spleen, and lymph node involvement, marrow blast and lymphocyte percentage, and peripheral blast and lymphocyte count did not significantly affect response to induction therapy.
Induction toxicity:
Toxicity of the induction regimen could be evaluated in 345 of the 353 eligible patients. The remaining eight patients included seven with major treatment deviations, such as treatment with leucovorin (four patients), no treatment due to refusal (two), and one patient who did not receive cyclophosphamide. The eighth patient's toxicities could not be evaluated due to inadequate data submission. Among the 345 evaluated patients, 52 (15%, CI 11-19%) died of treatment-related causes, most commonly infection either alone (39 patients) or combined with acute respiratory distress syndrome (ARDS), congestive heart failure and ARDS, hemorrhage, or ileus (one each). The nine remaining fatalities were due to CNS hemorrhage (four), leukoencephalopathy, bowel perforation, tumor lysis, ARDS with concurrent pul-monary and gastrointestinal hemorrhage, or aspiration. Nonfatal infection was observed in 130 patients (38%, CI 33-43%). The majority of patients developed neutropenia and/or thrombocytopenia. Ileus, seen in eight patients, was the most frequent grade 4 toxicity after infection and hematologic toxicity. Other non-hematologic toxicities of lesser grade affecting large numbers of patients included mucositis/stomatitis (123 patients), neurotoxicity (122 patients), ileus/constipation in 106 patients and nausea/vomiting/anorexia in 64 patients. The risk of fatal induction toxicity increased significantly with age (P Ͻ 0.0001), ranging from 6% for age 15-34 up to 37% for patients over 50 (Table 5) .
Post-remission therapy (SWOG 8419) Patients and treatment:
Of the 218 patients who achieved complete remission, 19 were not registered for SWOG-8419 due to induction toxicity or other medical reasons (eight patients), refusal or poor compliance (five), early relapse or death (four), or intention to pursue bone marrow transplantation (two). Three additional patients were registered for SWOG 8419 before meeting all criteria for CR, and a fourth relapsed prior to randomization. Thus 195 patients were eligible for the randomization between arms I (96 patients) and II (99). Characteristics of these patients are listed in Table 6 . Ten of these 195 patients (eight randomized to arm I and two to arm II) received the wrong consolidation regimen due to errors in recording the treatment assignments. Because of this Table 6 Characteristics of post-remission patients at the start of induction Leukemia unusually high error rate, toxicity, survival and DFS were analyzed in relation not only to assigned treatment (ie on the basis of 'intent-to-treat') but to treatment actually received as well. Six of the 195 patients received no protocol post-remission therapy because of early relapse or treatment refusal, but are included in the analyses.
Of the 96 patients randomized to arm I (L10M), 45 relapsed or died while on consolidation or maintenance, 22 patients completed all treatment as planned; 29 others were removed from treatment early due to toxicity (13 patients), refusal (eight) or other/unknown reasons (eight). Similar results were seen for the 98 patients randomized to arm II (DAT/Lasp/MTX): 52 relapsed or died; 20 completed all treatment; 26 were removed from treatment due to toxicity (nine), refusal (nine), or other reasons (eight).
Disease-free survival:
For the analysis of disease-free survival (DFS), 62 patients in arm I and 62 in arm II had documented relapses. Another 20 patients (six in arm I, 14 in arm II) died without report of relapse, the majority due to infection following this regimen (nine patients) or to complications of marrow transplantation while in remission (four patients).
There was no significant difference in DFS between the two arms based on assigned treatment, with an estimated hazard ratio (arm II relative to arm I) of 1.14 (CI 0.80-1.63 and P = 0.46 based on proportional hazards regression analysis with stratification by age, WBC and Philadelphia chromosome status) (Figure 1 ). The median DFS was 18 months (95% CI 11-23 months) for arm I and 20 months (95% CI 12-24 months) for arm II. Estimated DFS at 5 years is 32% (95% CI 23-42%) for arm I and 25% (95% CI 16-33%) for arm II. In unstratified multiple proportional hazards regression analysis only the three stratification factors were found to have prognostic significance. DFS decreased with increasing age (P = 0.0017) and increasing WBC (P = 0.012), and there was significant heterogeneity of DFS among the three categories of Philadelphia chromosome status (P = 0.0071). As expected, adjusting for these factors in the unstratified multiple regression analysis had no impact on the nonsignificance of the treatment effect (P = 0.24). Among the three groups defined by Philadelphia chromosome status, the Ph+ patients had the poorest DFS (median 11 months, 95% CI 3-14
Figure 1
Disease-free survival by treatment arm for patients receiving consolidation (SWOG 8419). months), those with unknown Ph status had the best DFS (median 44 months, 95% CI 22-65 months), and the Ph-negative patients had intermediate DFS (median 16 months, 95% CI 10-20 months). The difference in DFS between Ph+ and Ph-negative patients was only marginally significant (P = 0.069). Among the 134 patients with immunophenotypic markers of B cell, T cell, or null lineage, there was no significant heterogeneity of DFS among the three lineage groups (P = 0.45).
Analyses based on treatments actually received gave virtually identical results. In particular, stratified comparisons of the two groups defined by treatment received indicate no significant difference (P = 0.68).
Survival:
Of the 195 eligible patients, 134 have died (64 patients randomized to arm I, 70 to arm II). Duration of follow-up for the other 61 patients ranged from 22 months to 12.7 years (median 9.7 years). Based on assigned treatments, there was no significant difference in survival from randomization between the two arms (estimated hazard ratio 1.18 with CI 0.81-1.70 and P = 0.39 from the stratified analysis; see Figure 2 ). In unstratified multiple regression analysis, only two factors with significant, independent prognostic effects were identified: survival decreased with increasing age (P = 0.0006; Figure 3 ) and with increasing WBC (P = 0.0047; see Figure 4 ). After accounting for these two factors, there was no significant heterogeneity among the three categories of Philadelphia chromosome status (positive vs negative vs unknown; P = 0.22), and there was still no significant difference between the two treatment arms (P = 0.31). Among the 134 patients with immunophenotypic markers of B cell, T cell, or null lineage, there was no significant heterogeneity of survival among the three lineage groups (P = 0.44).
As in the analysis of DFS, results for survival were essentially unchanged when based on treatment actually given rather than assigned treatments. In particular, there was no significant difference in the stratified analysis of survival (P = 0.58).
Toxicity:
Eleven patients who either received no protocol post-remission therapy or for whom documentation was inad-
Figure 2
Overall survival by treatment arm for patients receiving consolidation (SWOG 8419).
Figure 3
Overall survival by age (SWOG 8419). A total of 195 eligible patients with adult ALL in remission entered the postremission portion of the study. Tick marks indicate surviving patients.
Figure 4
The effect of WBC count on overall survival for patients receiving consolidation. A total of 195 eligible patients with adult ALL in remission entered the post-remission portion of the study. Tick marks indicate surviving patients. equate were omitted from analyses of toxicity. Eight of the remaining 184 patients died of toxicity during consolidation: three in arm I and four in arm II died of infections, and one patient in arm I died from pulmonary embolism. All eight received the consolidation to which they were randomized, so the rates of fatal toxicity for arms I and II were 4/91 (4%) and 4/93 (4%), respectively, based on assigned treatments (CI 1-11% for each arm). There were no toxicity-related deaths during maintenance therapy.
Hematologic toxicity was seen in most patients. Grade 4 granulocytopenia (ie absolute granulocyte count Ͻ250/mm 3 ) was seen at least once during consolidation and maintenance in 78 (86%) of 91 patients randomized to arm I and in 78 (84%) of 93 patients randomized to arm II. The corresponding rates of grade 4 thrombocytopenia (platelet count Ͻ25 000/mm 3 ) were 77% and 73%. The majority of patients in both arms experienced infections: 62/91 (68%) and 52/93 (56%) among patients randomized to arms I and II, respectively (P = 0.097). This difference appears somewhat more sig-nificant when based on treatments actually received: 61/85 (72%) vs 53/99 (54%) (P = 0.015). Nausea and vomiting were also somewhat more common among patients randomized to arm I (48/91 or 53%) compared to arm II (31/93 or 33%) (P = 0.011), but this difference was largely due to patients who experienced only nausea or vomiting controllable with medication. Grade 4 non-hematologic toxicity other than infection was seen in 5/91 (5%) patients randomized to arm I (mucositis in three, rash in one, and elevated bilirubin in one) and in 4/93 (4%) randomized to arm II (liver failure, exudative esophagitis, hypotension with fever, and allergic reaction). All nine of these patients received the consolidation therapy to which they were randomized.
Overall results
Of the entire group of 353 eligible patients, 276 have died. Median follow-up of the remaining 77 patients is 9.8 years (except for a patient lost to follow-up at 718 days, the living patients have survived between 4.1 and 12.9 years). The estimated median survival was 18 months (95% CI 15-20 months) and the estimated survival at 5 years was 25% (95% CI 20-29%). Multiple proportional hazards regression analysis of overall survival identified four factors with statistically significant and independent prognostic effects. Among the 331 patients for whom all of these factors were known, of whom 260 died, survival decreased with increasing age (P Ͻ 0.0001; Figure 5 ), increasing absolute peripheral lymphocyte count (APLC; P = 0.0039), and decreasing hemoglobin (P = 0.020). There was also significant heterogeneity of survival among FAB categories (L1 vs L2 vs all other; P = 0.0035). The detrimental effect of increasing age is not entirely accounted for by the increasing incidence of fatal toxicity. This was seen in an analysis of the 285 patients who survived at least 75 days after entering SWOG 8417, which excludes all but one death due to induction toxicity. Among these patients, survival after day 75 still decreased significantly with increasing age (P = 0.0001). The variation of survival among FAB categories was almost entirely due to poorer survival of patients with L2 disease compared to all other patients combined (P = 0.0011). After adjusting for these four factors, there was no significant variation of survival according to CNS disease status (positive vs negative vs unknown; P = 0.14), although the 14 CNS-posi-
Figure 5
Effect of age on overall survival of all patients.
Leukemia tive patients had poorer survival compared to all others combined (P = 0.059). As expected, APLC and WBC were highly correlated, and survival therefore tended to decrease with increasing WBC. However, WBC was not statistically significant (P = 0.12) when used in place of APLC in the multiple regression model for survival. For the 224 patients with ALL of B cell, T cell, or null lineage, 176 of whom died, there was no significant heterogeneity of survival among the three lineage groups (P = 0.60). Among all 218 eligible patients who achieved CR, 138 have relapsed and another 25 have died without report of relapse. The estimated median DFS of the 218 patients was 18 months (95% CI 13-22 months) and estimated DFS at 5 years was 28% (95% CI 22-34%). A pattern of prognostic factors similar to that for overall survival was seen in the multiple proportional hazards regression analysis of DFS. In particular, DFS decreased significantly with increasing age (P = 0.0008), increasing APLC (P = 0.0003), and decreasing hemoglobin (P = 0.0042), and was somewhat poorer for patients in the FAB L2 category compared to all others (P = 0.054). Unlike overall survival, however, DFS was highly significantly associated with WBC (P = 0.0006) when used in place of APLC in the multiple regression analysis. DFS did not vary significantly among patients with ALL of B cell, T cell, or null lineage (P = 0.39).
Discussion
Since the initial report from Memorial Sloan Kettering describing the use of the L10 protocol, there have been numerous attempts to improve the outcome for adults with ALL. Induction regimens using standard agents including vincristine, prednisone, and an anthracycline generally produce CR rates of 60-80% in large multi-institutional trials, particularly for those patients less than 50 years of age ( Table 7 ). The addition of agents such as L-asparaginase or cyclophosphamide or intensification of anthracycline dosage may improve the CR rate to greater than 80%. 16, 17 
L-asp
Chemotherapeutic agents for induction: V, vincristine; P, prednisone; Dox, adriamycin; D, daunomycin; C, cyclophosphamide; Lasp, L-asparaginase; Ara-c, cytosine arabinoside; M, methotrexate; MP, 6-mercaptopurine.
Leukemia
The optimal post-remission therapy is undefined. The Southwest Oncology Group experience with the L10M consolidation suggested that this approach was relatively toxic and did not prevent relapse. The apparent decrease in toxicity of the DAT protocol in the L17 regimen as well as the demonstrated effectiveness of the Capizzi regimen in childhood ALL encouraged incorporation of these two approaches into a consolidation regimen. The comparison of the two post-remission arms on this study showed no significant difference in overall or DFS. Thus, this study did not identify a superior consolidation regimen with respect to agents, schedule of administration, and duration of consolidation. There were also no clearly important differences in toxicity, although infectious complications and nausea/vomiting were somewhat less frequent in the DAT/MTX/L-asparaginase consolidation arm.
Despite the apparent effectiveness of escalation of L-asparaginase and methotrexate in the treatment of ALL in children, this study did not suggest a benefit for this approach in adults. One possible explanation for the failure of this approach is the difference in drug metabolism between children and adults. Inhibition of purine synthesis by methotrexate also depends, in part, on the presence of polyglutamated forms of methotrexate which inhibit several enzymes not inhibited by methotrexate alone. The increased presence of long-chain methotrexate polyglutamates in vitro correlates with improved outcome in pediatric B cell leukemias. 18 B-lineage blasts in adults with ALL accumulate lower levels of methotrexate polygluatamates when compared to children with ALL. 19 Thus, it is possible that despite escalation of the dose of methotrexate, insufficient levels were obtained to expect a significant therapeutic benefit with this approach.
There are several characteristics that have been associated with an adverse outcome in adult ALL. Such factors that have been previously identified which predict for a shorter survival include age greater than 35, WBC Ͼ30 000/l, B cell or null phenotype, L2 or L3 phenotype, and the presence of the Philadelphia chromosome. 20, 21 In this study, overall and DFS were significantly affected by age, WBC or peripheral lymphocyte count, hemoglobin, and FAB classification. Furthermore, despite the small sample size, the presence of CNS involvement at diagnosis had a striking effect on outcome for those patients under age 50. Among the patients who achieved remission and were registered for post-remission therapy on SWOG 8419, DFS and overall survival decreased significantly with increasing age, increasing white count, and the presence of the Philadelphia chromosome.
The association between increasing age and poor outcome was quite striking in this study. The suggestion that increasing age adversely affected prognosis has been previously described. 22, 23 The estimated distributions of DFS were quite similar for patients in the 15-34 and 35-49 age groups, while those of age 50 and older fared very poorly (see Figures 3 and  5) . The joint effects of age and white count are illustrated in Figures 6 and 7 . For the 106 patients with age Ͻ50 and WBC Ͻ30 000 prior to induction, survival and DFS (measured from the time of registration on 8419) are 47% (95% CI 38-57%) and 37% (95% CI 27-46%), respectively, at 7 years. In contrast, the 63 patients age Ͻ50 but with WBC у30 000 at presentation had 7-year survival and DFS of 19% (95% CI 9-29%) and 16% (95% CI 7-25%), respectively. Of the 19 patients of age у50 with WBC Ͻ30 000, 17 relapsed or died of nonrelapse causes within 46 months, one was lost to follow-up 22 months after entering study 8419, and the final patient remains alive without report of relapse at 7.6 years. Finally, all seven patients over 50 with WBC Ͼ30 000 relapsed and The effect of age and WBC on DFS for those patients receiving consolidation (SWOG 8419).
Figure 7
The effect of age and WBC on overall survival for patients receiving consolidation (SWOG 8419). died within 21 months of registration on SWOG 8419. The presence of an elevated WBC has long been identified as an adverse prognostic feature in newly diagnosed patients with ALL. These data suggest that patients over the age of 50 fare poorly, and for those patients less than 50, an elevated WBC confers a prognosis similar to that seen in patients over age 50.
Those patients who are older or who have an elevated WBC appear to have a more biologically aggressive disease. The mechanism for this behavior is not well understood. Features associated with this group of patients may include adverse genetics in this group and/or the presence of CD34 expression. 24, 25 The poor outcome for patients over age 50 is reminiscent of results for older patients diagnosed with acute myelogenous leukemia (AML). The presence of the MDR phenotype and preceding myelodysplasia has been identified as predictive of poor prognosis in AML; data supporting such an association in ALL have been less well defined and need to be investigated as a possible mechanism of the aggressive biology seen in older patients with ALL.
Another factor associated with decreased complete remission rate was the presence of CNS disease. Despite the relatively small number of patients involved, the presence of CNS involvement at diagnosis appears to be associated with an extremely low probability of achieving a complete response. All of these patients were under age 50 and yet the CR rate was only 29% (CI 8-58%); this also appears to be independent of an elevated WBC. An elevated WBC at presentation has been previously associated with increased likelihood of CNS involvement or recurrence but CNS involvement by itself has not been previously identified as a significant prognostic factor. 3, 21 However, in this study, the presence of leukemic meningitis at presentation predicted a biologically aggressive disease and poor outcome.
Efforts to improve therapy of adult ALL will require improved induction and consolidation regimens, particularly for those patients with adverse biologic characteristics. The CR rate of 62% seen in the induction phase of this study is similar to the 68% CR rate obtained in the previous Southwest Oncology Group experience (SWOG 8001) using an identical regimen. The relatively low response rates seen in this study and SWOG 8001 compared to other reports, may reflect the inclusion of older patients and to a lesser extent, patients with known CNS involvement or patients known to be Ph+.
Recently, investigators have utilized more intensive induction regimens with some reporting improved CR rates. 16, 17, 26 However, these regimens may not be appropriate for patients over age 50 who need intensive therapy for their biologically aggressive disease and yet are not able to tolerate an aggressive approach to their disease. While the L10 regimen is reasonably well tolerated, one of the potential difficulties of the L10 induction regimen is the relatively prolonged administration of chemotherapeutic agents. Several investigators have suggested that those patients who achieve rapid cytoreduction and enter a remission rapidly have an improved prognosis when compared to those patients who take longer to achieve a remission. 16, 27 In this regimen, the doxorubicin and cyclophosphamide are not given until day 16; thereby perhaps delaying response and minimizing the effectiveness of these agents. Most of the newer induction programs administer these agents during the first few days of treatment to produce rapid cytoreduction.
Other investigators have explored alternate approaches to consolidation therapy including prolonged duration of consolidation or more intensive consolidation regimens. Prolonged consolidation with alternating intensive regimens monthly for 9 months duration has been published by Linker et al 16 with promising results in younger patients. Whether such an approach is beneficial, particularly for elderly patients, has yet to be determined is randomized trials.
Other intensive consolidation strategies include high-dose chemotherapy without stem cell support or marrow ablative regimens with either autologous or allogeneic stem cell transplantation. The most common high-dose, non-myeloablative approach is the administration of high-dose cytosine arabinoside (HiDAC). One rationale for such an approach is the CNS penetration of HiDAC for presumed treatment of CNS leukemia. Most trials of HiDAC have used this approach in relapsed patients, and there are relatively few trials where this has been utilized as part of initial consolidation therapy. However, the report by Dekker et al 25 is somewhat disappointing with a 5-year DFS of those patients entering consolidation of 24%. Similar results have been reported by other investigators but maintenance therapy was omitted in these trials. 28 The use of high-dose therapy with hematopoietic rescue as part of initial consolidation is also under investigation. Allogeneic transplantation has traditionally been employed for patients in first relapse. A retrospective analysis of patients treated in first CR compared survival data from the International Bone Marrow Transplant Registry (IBMTR) vs patients in the German ALL Leukemia trials. The 5-year DFS for chemotherapy was 38% (95% CI 33-43%) and for allogeneic transplant was 44% (95% CI 37-52%). However, patients at greater risk of relapse were more likely to have received a transplant. 2, 29 A study by Attal et al 30 evaluated autologous vs allogeneic bone marrow transplant as consolidation therapy. 30 The 3-year DFS post-CR was higher in the allogeneic transplant group (68% vs 26%; P Ͻ 0.001). When autologous transplant was compared to chemotherapy as post-remission therapy by Fiere et al, 31 there were similar 3-year DFS and survival durations between the two arms although late relapses after 36 months were more frequent in the chemotherapy arm. No randomized studies have been performed comparing chemotherapy to allogeneic transplant in first remission in adult ALL. Several trials, including SWOG 9400, are now underway assigning high risk patients with a matched allogeneic donor to transplant whereas those who do not have a matched donor will receive chemotherapy.
Future progress in the treatment of adult acute lymphoblastic leukemia may require improvements in supportive care options through the use of agents such as growth factors which could potentially permit delivery of more intensive induction or post-remission therapies. Recent studies have demonstrated that myeloid growth factors may permit delivery of dose-intensive therapy in ALL. 33 Fifteen per cent of patients entered on SWOG 8417/19 died of induction toxicity, the majority from infection or bleeding; similar numbers of toxic deaths have been seen in other large co-operative group trials. Efforts to decrease deaths due to toxicity should improve the outcome for these patients.
More importantly, an improved understanding of the biology of adult ALL and why it appears to be a different disease when compared to childhood ALL is critical to improve the outcome of these patients. Further understanding of cytogenetic abnormalities, multidrug resistance, and detection of minimal residual disease may lead to improvements in the therapy for acute lymphoblastic leukemia. Risk-adapted therapy based on biologic features of the patients leukemia may permit appropriate therapy for the individual patient. 32 For the time being, however, current standard approaches are associated with a 60-90% remission rate and a long-term diseasefree survival of 25-40%. The results of this trial are consistent with these expectations.
